Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1998 2
1999 3
2000 2
2001 1
2002 1
2003 1
2004 4
2005 6
2006 3
2007 10
2008 4
2009 13
2010 26
2011 17
2012 20
2013 14
2014 22
2015 25
2016 15
2017 15
2018 15
2019 11
2020 3
2021 6
2022 6
2023 14
2024 13
2025 8
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

244 results

Results by year

Filters applied: . Clear all
Page 1
A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia.
Najarian D, Sanga P, Wang S, Lim P, Singh A, Robertson MJ, Cohen K, Schotte A, Milz R, Venkatasubramanian R, T'Jollyn H, Walling DP, Galderisi S, Gopal S. Najarian D, et al. Int J Neuropsychopharmacol. 2022 Mar 17;25(3):238-251. doi: 10.1093/ijnp/pyab071. Int J Neuropsychopharmacol. 2022. PMID: 34791283 Free PMC article. Clinical Trial.
BACKGROUND: This double-blind (DB), randomized, parallel-group study was designed to evaluate efficacy and safety of paliperidone palmitate 6-month (PP6M) formulation relative to paliperidone palmitate 3-month (PP3M) formulation in patients with schizo …
BACKGROUND: This double-blind (DB), randomized, parallel-group study was designed to evaluate efficacy and safety of paliperidone …
Prospective, randomized, multicenter clinical trial evaluating longitudinal changes in brain function and microstructure in first-episode schizophrenia patients treated with long-acting injectable paliperidone palmitate versus oral antipsychotics.
Wang C, Tishler TA, Oughourlian T, Nuechterlein KH, de la Fuente-Sandoval C, Ellingson BM. Wang C, et al. Schizophr Res. 2023 May;255:222-232. doi: 10.1016/j.schres.2023.03.040. Epub 2023 Apr 3. Schizophr Res. 2023. PMID: 37019033 Free article. Clinical Trial.
However, whether a long-acting injectable antipsychotic (paliperidone palmitate [PP]), available in monthly and every-3-months formulations, is more effective than oral antipsychotics (OAP) in improving cerebral organization has been unclear. ...
However, whether a long-acting injectable antipsychotic (paliperidone palmitate [PP]), available in monthly and every-3-months …
Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST).
Winter-van Rossum I, Weiser M, Galderisi S, Leucht S, Bitter I, Glenthøj B, Hasan A, Luykx J, Kupchik M, Psota G, Rocca P, Stefanis N, Teitelbaum A, Bar Haim M, Leucht C, Kemmler G, Schurr T; EULAST Study Group; Davidson M, Kahn RS, Fleischhacker WW. Winter-van Rossum I, et al. Lancet Psychiatry. 2023 Mar;10(3):197-208. doi: 10.1016/S2215-0366(23)00005-6. Epub 2023 Jan 27. Lancet Psychiatry. 2023. PMID: 36716759 Clinical Trial.
Patients aged 18 years and older, with DSM-IV schizophrenia (as confirmed by the Mini International Neuropsychiatric Interview 5 plus) and having experienced their first psychotic episode from 6 months to 7 years before screening, were randomly allocated (1:1:1:1) using block ran …
Patients aged 18 years and older, with DSM-IV schizophrenia (as confirmed by the Mini International Neuropsychiatric Interview 5 plus) and h …
Initial severity of the Positive and Negative Syndrome Scale (PANSS)-30, its main subscales plus the PANSS-6, and the relationship to subsequent improvement and trial dropout: a pooled participant-level analysis of 18 placebo-controlled risperidone and paliperidone trials.
Hieronymus F, Correll CU, Østergaard SD. Hieronymus F, et al. Transl Psychiatry. 2023 Jun 7;13(1):191. doi: 10.1038/s41398-023-02491-6. Transl Psychiatry. 2023. PMID: 37286548 Free PMC article. Clinical Trial.
We assessed the relationship between initial severity and antipsychotic-placebo separation as measured by PANSS-30 and four PANSS symptom subscales: the positive (PANSS-POS), negative (PANSS-NEG), general (PANSS-GEN) and 6-item (PANSS-6) subscales, using patient-level data from 1 …
We assessed the relationship between initial severity and antipsychotic-placebo separation as measured by PANSS-30 and four PANSS symptom su …
Three-Year Outcomes of 6-Month Paliperidone Palmitate in Adults With Schizophrenia: An Open-Label Extension Study of a Randomized Clinical Trial.
Correll CU, Johnston K, Turkoz I, Gray J, Sun L, Doring M, Sajatovic M. Correll CU, et al. JAMA Netw Open. 2024 Jul 1;7(7):e2421495. doi: 10.1001/jamanetworkopen.2024.21495. JAMA Netw Open. 2024. PMID: 39018073 Free PMC article. Clinical Trial.
IMPORTANCE: Long-acting injectable (LAI) antipsychotics have the potential to improve adherence and symptom control in patients with schizophrenia, promoting long-term recovery. Paliperidone palmitate (PP) once every 6 months is the first and currently only LAI anti …
IMPORTANCE: Long-acting injectable (LAI) antipsychotics have the potential to improve adherence and symptom control in patients with schizop …
Randomized open-label study of second-generation antipsychotics for the treatment of schizophrenia: 104-week final results of the JUMPs study assessing treatment discontinuation, remission, and social functioning.
Ishigooka J, Nakagome K, Ohmori T, Iwata N, Inada K, Iga JI, Kishi T, Fujita K, Kikuchi Y, Shichijo T, Tabuse H, Koretsune S, Terada H, Terada H, Kishimoto T, Tsutsumi Y, Ohi K. Ishigooka J, et al. BMC Psychiatry. 2024 Sep 5;24(1):600. doi: 10.1186/s12888-024-06031-4. BMC Psychiatry. 2024. PMID: 39237918 Free PMC article. Clinical Trial.
BACKGROUND: We report the final results of treatment with aripiprazole, blonanserin, and paliperidone from the Japan Useful Medication Program for Schizophrenia (JUMPs), a 104-week naturalistic study. ...RESULTS: In total, 251 patients received aripiprazole (n = 82), blona …
BACKGROUND: We report the final results of treatment with aripiprazole, blonanserin, and paliperidone from the Japan Useful Medicatio …
Model-Informed Clinical Development of 6-Monthly Injection of Paliperidone Palmitate in Patients with Schizophrenia: Dosing Strategies Guided by Population Pharmacokinetic Modeling and Simulation (Part II).
T'jollyn H, Venkatasubramanian R, Neyens M, Gopal S, Russu A, Nandy P, Perez-Ruixo JJ, Ackaert O. T'jollyn H, et al. Eur J Drug Metab Pharmacokinet. 2024 Jul;49(4):491-506. doi: 10.1007/s13318-024-00899-z. Epub 2024 May 20. Eur J Drug Metab Pharmacokinet. 2024. PMID: 38769284 Clinical Trial.
BACKGROUND AND OBJECTIVE: Paliperidone palmitate 6-month (PP6M) intramuscular (IM) injection is the longest-acting treatment available for patients with schizophrenia. ...METHODS: The extensive analysis database included 15,932 paliperidone samples from 700 p …
BACKGROUND AND OBJECTIVE: Paliperidone palmitate 6-month (PP6M) intramuscular (IM) injection is the longest-acting treatment a …
Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.
Berwaerts J, Liu Y, Gopal S, Nuamah I, Xu H, Savitz A, Coppola D, Schotte A, Remmerie B, Maruta N, Hough DW. Berwaerts J, et al. JAMA Psychiatry. 2015 Aug;72(8):830-9. doi: 10.1001/jamapsychiatry.2015.0241. JAMA Psychiatry. 2015. PMID: 25820612 Clinical Trial.
Of the 506 patients enrolled (aged 18-70 years; DSM-IV-TR diagnosis of schizophrenia), 305 were randomized to 3-month paliperidone palmitate (n = 160) or placebo (n = 145) in the DB phase. INTERVENTIONS: Patients received once-monthly doses of the 1-month formulatio …
Of the 506 patients enrolled (aged 18-70 years; DSM-IV-TR diagnosis of schizophrenia), 305 were randomized to 3-month paliperidone …
Effects of Long-Acting Injectable Paliperidone Palmitate on Clinical and Functional Outcomes in Patients With Schizophrenia Based on Illness Duration.
Kim S, Kim S, Koh M, Choi G, Kim JJ, Paik IH, Kim SH, Choi YS, Lee Y, Suh J, Takeuchi H, Uchida H, Kim E. Kim S, et al. J Clin Psychiatry. 2021 Jan 12;82(1):20m13446. doi: 10.4088/JCP.20m13446. J Clin Psychiatry. 2021. PMID: 33434958 Free article. Clinical Trial.
OBJECTIVE: This study aimed to examine the degree of clinical and functional improvement after paliperidone long-acting injectable (LAI) administration according to the duration of illness. ...Improvements after starting paliperidone LAI were compared among patients …
OBJECTIVE: This study aimed to examine the degree of clinical and functional improvement after paliperidone long-acting injectable (L …
244 results